PUBLICATION
- Cheng L, Pandya PH, Liu E, Chandra P, Wang L, Murray ME, Carter J, Ferguson M, Saadatzadeh MR, Bijangi-Visheshsaraei K, Marshall M, Li L, Pollok KE, Renbarger JL. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma. BMC Med Genomics. 2019 Jan 31;12(Suppl 1):23. doi: 10.1186/s12920-018-0456-5. PMID: 30704460; PMCID: PMC6357363.
- Pandya PH, Cheng L, Saadatzadeh MR, Bijangi-Vishehsaraei K, Tang S, Sinn AL, Trowbridge MA, Coy KL, Bailey BJ, Young CN, Ding J, Dobrota EA, Dyer S, Elmi A, Thompson Q, Barghi F, Shultz J, Albright EA, Shannon HE, Murray ME, Marshall MS, Ferguson MJ, Bertrand TE, Wurtz LD, Batra S, Li L, Renbarger JL, Pollok KE. Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma. Cancers (Basel). 2020 Aug 26;12(9):2426. doi: 10.3390/cancers12092426. PMID: 32859084; PMCID: PMC7564419.
- Tang S, Roberts RD, Cheng L, Li L. Osteosarcoma Multi-Omics Landscape and Subtypes. Cancers (Basel). 2023 Oct 13;15(20):4970. doi: 10.3390/cancers15204970. PMID: 37894336; PMCID: PMC10605601.
- Zhang Z, Cheng L, Zhang Q, Kong Y, He D, Li K, Rea M, Wang J, Wang R, Liu J, Li Z, Yuan C, Liu E, Fondufe-Mittendorf YN, Li L, Han T, Wang C, Liu X. Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer. Adv Sci (Weinh). 2021 Jul;8(13):e2101458. doi: 10.1002/advs.202101458. Epub 2021 May 29. Erratum in: Adv Sci (Weinh). 2022 Jul;9(20):e2202572. doi: 10.1002/advs.202202572. PMID: 34051063; PMCID: PMC8261504.
- Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE Jr, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer. 2021 Nov 11;7(1):142. doi: 10.1038/s41523-021-00349-y. PMID: 34764307; PMCID: PMC8586340.
- Huo Y, Shao S, Liu E, Li J, Tian Z, Wu X, Zhang S, Stover D, Wu H, Cheng L, Li L. Subpathway Analysis of Transcriptome Profiles Reveals New Molecular Mechanisms of Acquired Chemotherapy Resistance in Breast Cancer. Cancers (Basel). 2022 Oct 5;14(19):4878. doi: 10.3390/cancers14194878. PMID: 36230801; PMCID: PMC9563670.
- Wang L, Li J, Liu E, Kinnebrew G, Zhang X, Stover D, Huo Y, Zeng Z, Jiang W, Cheng L, Feng W, Li L. Identification of Alternatively-Activated Pathways between Primary Breast Cancer and Liver Metastatic Cancer Using Microarray Data. Genes (Basel). 2019 Sep 25;10(10):753. doi: 10.3390/genes10100753. PMID: 31557971; PMCID: PMC6826985.
- Cheng L, Schneider BP, Li L. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients. J Am Med Inform Assoc. 2016 Jul;23(4):741-9. doi: 10.1093/jamia/ocw004. Epub 2016 Apr 23. PMID: 27107440; PMCID: PMC4926742.
- Cheng L, Majumdar A, Stover D, Wu S, Lu Y, Li L. Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine. Genes (Basel). 2020 Feb 28;11(3):263. doi: 10.3390/genes11030263. PMID: 32121160; PMCID: PMC7140855.
- Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp ZD, Kirma NB, Jin VX, Huang TH. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell. 2013 Aug 12;24(2):197-212. doi: 10.1016/j.ccr.2013.07.007. PMID: 23948299; PMCID: PMC3890247.